布伦图西马布维多丁在复发性或耐火性周围T细胞淋巴瘤中添加到吉姆西塔:LYSA第二阶段研究
Olivier Tournilhac1, Krimo Bouabdallah2, Solene Lecolant3
1Clermont-Ferrand University Hospital, UCA, EA7453 Chelter CIC-1405, Clermont-Ferrand, France.
布伦图西马布维多丁 (BV) 结合吉姆西塔,在复发性或耐火性外围T细胞淋巴瘤 (PTCL) 中显示了46.5%的整体应答率. 这种组合疗法为PTCL患者提供了新的治疗选择.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 临床试验 临床试验
背景情况:
- 复发性或难治性外围T细胞淋巴瘤 (PTCL) 的治疗选择有限.
- 布伦图西马布维多丁 (BV) 是一种抗体药物结合剂,有效治疗CD30表达性淋巴瘤.
- 吉姆西塔是一种用于化疗的核类型.
研究的目的:
- 评估布伦图西马布维多丁 (BV) 结合凝胺诱导,然后在复发性或耐火性 (R/R) PTCL 患者中维护 BV 的疗效和安全性.
- 评估整体反应率 (ORR),反应持续时间 (DOR),无进展生存率 (PFS) 和整体生存率 (OS).
主要方法:
- 共有71名R/R PTCL患者和至少5%的CD30阳性细胞被纳入.
- 患者接受了4个周期的凝丁加BV诱导疗法.
- 响应的患者接受了长达12个周期的BV维持疗法.
主要成果:
- 总体响应率 (ORR) 为46.5%,诱导后的完整响应率为19.7%.
- 中位数DOR,PFS和OS分别为15.8个月,4.5个月和12.9个月.
- 在ALCL,TFHL和PTCL-NOS亚型中观察到更高的疗效,在高基线可溶性CD30和反应/生存之间存在负相关性.
结论:
- 布伦图西马布维多丁与格姆西塔结合,然后进行BV维护,是R/R PTCL的有效治疗选择.
- 该疗法显示出有希望的反应率和生存结果.
- 可溶性CD30水平可以预测特定PTCL亚型的治疗反应和存活率.
更多相关视频
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
相关概念视频
Treatment Resistant Cancers
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
